BIIB : Summary for Biogen Inc. - Yahoo Finance

U.S. Markets close in 6 hrs 25 mins

Biogen Inc. (BIIB)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
281.96-2.79 (-0.98%)
As of 9:35AM EST. Market open.
People also watch
CELGGILDREGNAMGNALXN
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close284.75
Open284.28
Bid282.82 x 100
Ask286.23 x 300
Day's Range281.08 - 284.55
52 Week Range223.02 - 333.65
Volume98,645
Avg. Volume1,772,777
Market Cap61.35B
Beta0.34
PE Ratio (TTM)15.95
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • American City Business Journals21 minutes ago

    Biogen to pay $1.25B settlement in multiple sclerosis drug case

    Biogen has reached a $1.25 billion settlement and licensing agreement with Danish biotech Forward Pharma to resolve a dispute over a patent on the Cambridge company’s top-selling multiple sclerosis drug. The deal, which gives Biogen (BIIB) a license to Forward Pharma’s intellectual property, could help the Cambridge company extend the life of Tecfidera, which accounts for around a third of its total revenues. Forward Pharma (FWP) had claimed that Biogen infringed on its patent regarding the dosage of the drug’s key ingredient.

  • MarketWatch2 hours ago

    Forward Pharma stock skyrockets 53% on $1.25 bln cash licensing agreement with Biogen

    Biogen Inc. said Tuesday morning that it had agreed to pay $1.25 billion in cash to license all of Forward Pharma's intellectual property, sending Forward Pharma shares skyrocketing 52.6% in pre-market ...

  • Business Wire2 hours ago

    Biogen and Forward Pharma Agree to Enter into Settlement and License Agreement

    Biogen Inc. today announced that it has agreed to enter into a settlement and license agreement with Forward Pharma, subject to the approval of Forward Pharma’s shareholders and other customary conditions.